2017-07-13T23:10:32 CET


Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

Adhoc: MorphoSys Announces That Its Licensee Janssen Has Received US FDA Approval for Tremfya(TM) (Guselkumab) for the Treatment of Moderate to Severe Plaque Psoriasis

First antibody generated from MorphoSys's HuCAL library technology to receive marketing approval

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; OTC: MPSYY) announced today that its licensee Janssen Biotech, Inc. (Janssen), has reported that the U.S. Food and Drug Administration (FDA) has approved Tremfya(TM) (guselkumab) for the treatment of patients with moderate to severe plaque psoriasis. Tremfya is a fully human anti-IL-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys's proprietary HuCAL antibody library technology. MorphoSys will receive a milestone payment from Janssen in connection with the BLA approval. Financial details were not disclosed.

MorphoSys will provide information on on financial guidance at a later date.

End of adhoc announcement

MorphoSys AG published this content on 14 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 13 July 2017 21:19:04 UTC.

Original documenthttps://www.morphosys.com/media-investors/media-center/adhoc-morphosys-announces-that-its-licensee-janssen-has-received-us-fda

Public permalinkhttp://www.publicnow.com/view/DF1059A166B971E873BB7D881048102ED5FA2FBD